Evaluation of physicochemical and microbiological stability of liquid preparation from tizanidine hydrochloride tablets - a Hospital concern
DOI:
https://doi.org/10.1590/s2175-97902020000418896Keywords:
Tizanidine hydrochloride. Liquid preparation. Physicochemical and microbiological stability. High-performance liquid chromatographyAbstract
Tizanidine hydrochloride is a centrally acting skeletal muscle relaxant, used in the management of spasticity. This drug is commercially available only as tablets, which highlights the need to develop oral liquid formulations. In the hospital environment, this aspect is circumvented by the preparation of suspensions, to allow administration to children and adults with impaired swallowing, but there are no data regarding their stability. The purpose of this study was to evaluate the physicochemical andmicrobiological stability of liquid dosage forms prepared in the hospital environment from tizanidine hydrochloride tablets, applying high performance liquid chromatography (HPLC) and microbiological analysis. A simple and stability-indicating HPLC method was developed and validated for specificity, linearity, limits of detection and quantification, precision, accuracy and robustness. The liquid formulations were placed in amber PET and glass bottles, which were stored under three different conditions: at room temperature, under refrigeration and at 40 ºC. The liquid formulations were analyzed and demonstrated chemical stability for 56 days, allowing their use for long periods. However, the determination of microbiological stability showed that these formulations are prone to microbial contamination, which has dramatically reduced its stability to 7 days, in both bottles and at all evaluated temperatures.
Downloads
References
Balan S, Hassali MA, Mak VSL. Challenges in pediatric drug use: A pharmacist point of view. Res Social Adm Pharm. 2017;13(3):653-655.
Brazilian Pharmacopoeia. 5 ed. Brasília: Agência Nacional de Vigilância Sanitária; 2010.
Dudhe PB, Jadhav S, Sawarkar V, Nagras MA. Method Development and Validation for Simultaneous Determination of Aceclofenac and Tizanidine in Bulk and Marketed Formulation. Int.J. PharmTech Res. 2013;5(3):1212-1216.
García MC, Manzo RH, Jimenez-Kairuz AF. Extemporaneous benznidazole oral suspension prepared from commercially available tablets for treatment of Chagas disease in paediatric patients. Trop Med Int Health. 2015;20(7):864-870.
Gillicuddy AM, Kelly M, Crean AM, Sahm LJ. The knowledge, attitudes and beliefs of patients and their healthcare professionals around oral dosage form modification: A systematic review of the qualitative literature. Res Social Adm Pharm. 2017;13(4):717-726.
Guzmán DC, García EH, Olguín HJ, Jiménez FT. Medicamentos empleados em dosis pediátricas unitarias. Acta Pediatr Mex. 2012;33(1):44-47.
International Conference on Harmonization. ICH. Validation of analytical procedures: text and methodology Q2 R1. Geneva: International Conference on Harmonization; 2005. cited 2017 April 10 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf
Jones D. Pharmaceutics: dosage form and design. London: Pharmaceutical Press; 2008. p.5.
Kumar RS, Nathan PS, Nallasivan PK, Solomon WDS, Venkatnarayanan R. A validated reversed phase HPLC-method for the determination of aceclofenac and tizanidine in tablets. JPRHC. 2010;2(1):84-94.
Lwin EMP, Ellis D, Song Y, Turner S, Williams D, Garg S. Evaluation of the physical, chemical and microbiological stability of compounded carbimazole suspension. Res Social Adm Pharm. 2016a;12(5):e39-e40.
Lwin EMP, Zen WC, Ellis D, Song Y, Turner S, Williams D, et al. Evaluation of the physical, chemical and microbiological stability of compounded minoxidil suspension. Res Social Adm Pharm. 2016b;12(5):e39.
Nalluri BN, Sushmitha K, Sunandana B, Badu DP. Development and validation of RP-HPLC-PDA method for simultaneous estimation of baclofen and tizanidine in bulk and dosage forms. J Appl Pharm Sci. 2012;2(7):111-116.
Narajji C, Patel HR, Karvekar MD, Babu S. Simultaneous Estimation of Aceclofenac, Paracetamol and Tizanidine in Their Combined Dosage Forms by Spectrophotometric and RP- HPLC Method. J Anal Bioanal Techniques. 2011;2(4):2-4.
Nikkhah A, Mohammadi M, Ashrafi MR, Zamani GH. The efficacy and safety of tizanidine in treating spasticity in children with cerebral palsy. Iran J Child Neurol. 2011;5(3):19-22.
Palazon GR, Benavente VA, Arroyo RO. Protocol for tizanidine use in infantile cerebral palsy. A Pediatr (Barc). 2008;68(5):511-515.
Pelczar Jr MJ, Chan ECS, Krieg NR. Microbiologia: conceitos e aplicações. 2th ed. São Paulo: Makron Books do Brasil; 1997. p.147.
Qi ML, Wang P, Wang L. Validated liquid chromatography method for assay of tizanidine in drug substance and formulated product. Anal Chim Acta. 2002;478:171-177.
Rosa AM, Gerlin MCG, Alcântara IC, Sversut RA, Cardoso TFM, Rodrigues PO, et al. Desenvolvimento e estudo de estabilidade de formulações extemporâneas de uso oral a partir de comprimidos comerciais contendo espironolactona. Rev Ciênc Farm Básica Apl. 2014;35(3):385-392.
Santos L, Heineck L. Extemporaneous Oral Preparations. An Alternative forHospitalized Children. Lat Am J Pharm. 2011;30(5):996-1000.
Sweetman SC, editor. Martindale: the complete drug reference. 37th ed. London:Pharmaceutical Press; 2011. p. 2062-2063.
The United States Pharmacopeia. 38 ed. Rockville: The United States Pharmacopoeial Convention; 2015.
Wagstaff AJ, Bryson HM. Tizanidine: A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53(3):435-452.
Published
Issue
Section
License
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on line journal has open and free access.
